Suggested remit: To appraise the clinical and cost effectiveness of enfortumab vedotin with pembrolizumab within its marketing authorisation for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6607
Provisional Schedule
- Committee meeting:
- 07 October 2026
- Expected publication:
- 10 February 2027
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- MSD (pembrolizumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Action Bladder Cancer UK
- Professional groups
- Association of Cancer Physicians
- British Uro-Oncology Group
- Royal College of Radiologists
- Comparator companies
- Astellas Pharma (enfortumab vedotin)
- Amarox (cisplatin) – CAU not returned, not participating
- AstraZeneca (durvalumab)
- Bristol Myers Squibb (nivolumab) – CAU not returned, not participating
- Hospira UK (cisplatin, gemcitabine)
- Sandoz (cisplatin) – CAU not returned, not participating
- Sun Pharma (gemcitabine) – CAU not returned, not participating
- Synchrony (gemcitabine) – CAU not returned, not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- NHS Wales Joint Commissioning Committee
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 March 2026 | Invitation to participate |
| 23 January 2026 - 20 February 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6607 |
| 16 January 2026 | Following discussions with the company, this appraisal has been combined with ID6301. The combined appraisal will continue under ID6607, and the new title is "Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer". - Note added to the project documents |
| 07 November 2025 | In progress. Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early March 2026 when we will write to you about how you can get involved. |
| 07 February 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual